Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Capital Expenditures: 2009-2025

Historic Capital Expenditures for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $210.5 million.

  • UNITED THERAPEUTICS's Capital Expenditures rose 175.16% to $210.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.3 million, marking a year-over-year increase of 82.10%. This contributed to the annual value of $246.5 million for FY2024, which is 6.99% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Capital Expenditures is $210.5 million, which was up 238.42% from $62.2 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Capital Expenditures high stood at $210.5 million for Q3 2025, and its period low was $10.6 million during Q1 2021.
  • Its 3-year average for Capital Expenditures is $75.0 million, with a median of $65.7 million in 2023.
  • In the last 5 years, UNITED THERAPEUTICS's Capital Expenditures surged by 473.98% in 2021 and then tumbled by 44.05% in 2022.
  • UNITED THERAPEUTICS's Capital Expenditures (Quarterly) stood at $70.6 million in 2021, then slumped by 44.05% to $39.5 million in 2022, then surged by 99.24% to $78.7 million in 2023, then increased by 10.17% to $86.7 million in 2024, then soared by 175.16% to $210.5 million in 2025.
  • Its Capital Expenditures was $210.5 million in Q3 2025, compared to $62.2 million in Q2 2025 and $74.9 million in Q1 2025.